Skip to content
Subscriber Only
Business
Prognosis

Chinese Alzheimer’s Drug Gets U.S. Approval for Stateside Trial

  • Green Valley’s novel therapy was approved in China last year
  • First drug for the neuro-degenerative disease in 17 years
Geng Meiyu, key inventor of the drug GV-971, also a researcher of Shanghai Institute of Materia Medica under Chinese Academy of Sciences, shows the sample model of the new drug in Shanghai, east China, Nov. 3, 2019.

Geng Meiyu, key inventor of the drug GV-971, also a researcher of Shanghai Institute of Materia Medica under Chinese Academy of Sciences, shows the sample model of the new drug in Shanghai, east China, Nov. 3, 2019.

Photographer: Jin Liwang/Xinhua via Getty Images

Bloomberg News

Sign up for Next China, a weekly email on where the nation stands now and where it's going next.

A Chinese drugmaker has received approval from the Food and Drug Administration to start clinical trials in the U.S. for a breakthrough Alzheimer’s drug as it seeks global validation for the controversial therapy.

Shanghai Green Valley Pharmaceutical Co. got clearance on April 8 for the U.S. part of a global trial that seeks to enroll more than 2,000 patients with mild-to-moderate Alzheimer’s across North America, Europe and Asia, according to a company statement Sunday.